

FITC anti-mouse TER-119/Erythroid Cells Antibody

Catalog# / Size	116205 / 50 µg 116206 / 500 µg
Clone	TER-119
Regulatory Status	RUO
Other Names	Ly-76
Isotype	Rat IgG2b, κ
Description	The TER-119 antigen is a 52 kD glycophorin A-associated protein, also known as Ly-76. TER-119 is an erythroid-specific antigen expressed on early proerythroblasts to mature erythrocytes, but not on erythroid colony-forming cells (BFU-E, blast-forming unit erythroid, or CFU-E, colony-forming unit erythroid).

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	Day-14 fetal liver cells from a C57BL/6 mouse
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration	0.5 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Blue Laser (488 nm)
Application Notes	The TER-119 antibody is useful for distinguishing erythrocytes and cells in the erythroid lineage. Additional reported applications (for the relevant formats) include: immunoprecipitation ¹ , Western blotting ¹ , complement-mediated cytotoxicity ³ , and immunohistochemical staining of acetone-fixed frozen sections and formalin-fixed paraffin-embedded sections. Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 116253-116258).
Application References	<ol style="list-style-type: none"> 1. Kina T, <i>et al.</i> 2000. <i>Br. J. Haematol.</i> 109:280. (IP, WB) 2. Vannucchi AM, <i>et al.</i> 2000. <i>Blood</i> 95:2559. 3. Maraskovsky E, <i>et al.</i> 1996. <i>J. Exp. Med.</i> 184:1953. (CMCD) 4. Grisendi S, <i>et al.</i> 2005. <i>Nature</i> 437:147. (FC) 5. Bourdeau A, <i>et al.</i> 2007. <i>Blood</i> 109:4220. 6. Chappaz S, <i>et al.</i> 2007. <i>Blood</i> 110:3862. (FC) 7. Heuser M, <i>et al.</i> 2007. <i>Blood</i> 110:1639. (FC) 8. Gough SM, <i>et al.</i> 2014. <i>Cancer Discov.</i> 4:564. PubMed
(PubMed link indicates BioLegend citation)	
Product Citations	<ol style="list-style-type: none"> 1. Suzuki M, <i>et al.</i> 2015. <i>J Immunol.</i> 195: 1273-1281. PubMed 2. Katsumura KR, <i>et al.</i> 2018. <i>Proc Natl Acad Sci U S A.</i> 115:E10109. PubMed 3. Hou X, <i>et al.</i> 2020. <i>Cell Reports.</i> 28(1):172-189.e7.. PubMed

4. Furuhashi K, *et al.* 2017. Immunology. 151:227. [PubMed](#)
5. Lawson H, *et al.* 2021. Stem Cell Reports. 16:2784. [PubMed](#)
6. Bruggemann TR, *et al.* 2022. iScience. 25:105185. [PubMed](#)
7. Han X, *et al.* 2017. Int J Mol Sci. 10.3390/ijms18050942. [PubMed](#)
8. Ju W, *et al.* 2020. J Biomed Sci. 27:91. [PubMed](#)
9. Schönberger K, *et al.* 2022. Cell Stem Cell. 29:131. [PubMed](#)
10. Johnson KD, *et al.* 2022. Blood Adv. 6:1464. [PubMed](#)
11. Chen T, *et al.* 2021. JCI Insight. 6:. [PubMed](#)
12. Tan X, *et al.* 2021. Front Oncol. 11:768222. [PubMed](#)
13. Jin L, *et al.* 2016. Stem Cell Res. 16:40-53. [PubMed](#)
14. Davis FM, *et al.* 2019. Arterioscler Thromb Vasc Biol. 39:2353. [PubMed](#)
15. Enriquez AB, *et al.* 2022. iScience. 25:104305. [PubMed](#)
16. Agarwal S, *et al.* 2015. Cell Rep. 13: 2147-2158. [PubMed](#)
17. Greenblatt SM, *et al.* 2018. Cancer Cell. 33:1111. [PubMed](#)
18. Jiang X, *et al.* 2021. Sci Signal. 14:. [PubMed](#)
19. Krishack PA, *et al.* 2021. Am J Respir Cell Mol Biol. 64:569. [PubMed](#)
20. Enriquez AB, *et al.* 2022. iScience. 25:104305. [PubMed](#)
21. Geng T, *et al.* 2022. Methods Mol Biol. 2585:71. [PubMed](#)
22. Marjanovic ND, *et al.* 2020. Cancer Cell. 38(2):229-246.e13. [PubMed](#)
23. Grandl G, *et al.* 2016. Mol Metab. 5:937-947. [PubMed](#)
24. Park HB, *et al.* 2020. Oncoimmunology. 9:1772663. [PubMed](#)
25. Lu X, *et al.* 2016. Nat Commun. 7: 12719. [PubMed](#)
26. Li Y, *et al.* 2020. Cell Stem Cell. 27(5):732-747.e7. [PubMed](#)
27. Derecka M, *et al.* 2020. Nat Immunol. 26:121. [PubMed](#)
28. Greenwald AC, *et al.* 2019. J Exp Med. 216:215. [PubMed](#)
29. Srivastava S, *et al.* 2019. Cancer Cell. 35:489. [PubMed](#)
30. Elahi S, *et al.* 2020. Stem Cell Res. 43:101710. [PubMed](#)
31. Reismann D, *et al.* 2017. Nat Commun.. 10.1038/s41467-017-01538-9. [PubMed](#)
32. Guarnerio J, *et al.* 2015. Cancer Discovery. 5:396. [PubMed](#)
33. Ku C, *et al.* 2015. Genes Dev. 29: 1930-1941. [PubMed](#)
34. Crispin A, *et al.* 2020. J Clin Invest. 130:5245. [PubMed](#)
35. Lim CX, *et al.* 2020. Cell Rep. 3793:30. [PubMed](#)
36. Crowell PD *et al.* 2019. Cell Rep. 28(6):1499-1510 . [PubMed](#)
37. de Barros SC, *et al.* 2020. J Immunol. 205:2423. [PubMed](#)
38. Li CM, *et al.* 2020. Cell Reports. 33(13):108566. [PubMed](#)
39. Nowlan B, *et al.* 2019. Haematologica. 105:71. [PubMed](#)
40. Zhang W, *et al.* 2020. Nat Commun. 11:1187. [PubMed](#)
41. Chen R, *et al.* 2021. Cell Reports. 34(7):108751. [PubMed](#)
42. Lu Y, *et al.* 2020. Immunity. 52:782. [PubMed](#)
43. Dong X, *et al.* 2022. Front Immunol. 13:896472. [PubMed](#)
44. Wang S, *et al.* 2021. Commun Biol. 22:. [PubMed](#)
45. Hoffmann J, *et al.* 2021. Nat Commun. 12:3964. [PubMed](#)
46. Zhang Q, *et al.* 2022. Commun Biol. 5:544. [PubMed](#)
47. Clemente-Casares X, *et al.* 2017. Immunity. 47:974. [PubMed](#)
48. Golan K *et al.* 2018. Cell stem cell. 23(4):572-585 . [PubMed](#)
49. Zegarra-Ruiz DF *et al.* 2018. Cell host & microbe. 25(1):113-127 . [PubMed](#)
50. Krivtsov AV, *et al.* 2020. Cancer Cell. 36(6):660-673.e11.. [PubMed](#)
51. Mesa-Nuñez C, *et al.* 2022. Mol Ther Methods Clin Dev. 26:459. [PubMed](#)
52. Kim DJ, *et al.* 2020. Proc Natl Acad Sci U S A. 117:15837. [PubMed](#)
53. Rosnagl S, *et al.* 2016. PLoS Biol. 14: 1002562. [PubMed](#)
54. Zhang J, *et al.* 2019. Exp Hematol. 78:21:00. [PubMed](#)
55. Li K, *et al.* 2020. Nat Commun. 0.795138889. [PubMed](#)
56. Hidalgo San Jose L, *et al.* 2020. Cell Rep. 30:69. [PubMed](#)
57. Wang X, *et al.* 2022. Elife. 11:. [PubMed](#)
58. Koh BI, *et al.* 2020. Nat Commun. 3.143055556. [PubMed](#)
59. Goldberg EL, *et al.* 2021. Cell Metabolism. .: [PubMed](#)
60. Rivera CA, *et al.* 2022. Immunity. 55:129. [PubMed](#)
61. Awida Z, *et al.* 2021. Int J Mol Sci. 23:. [PubMed](#)
62. Guarnerio J, *et al.* 2018. Nat Commun. 9:66. [PubMed](#)
63. Liang Z, *et al.* 2022. iScience. 25:105233. [PubMed](#)
64. Gu Z, *et al.* 2021. Nat Genet. 53:672. [PubMed](#)

RRID AB_313706 (BioLegend Cat. No. 116205)
 AB_313707 (BioLegend Cat. No. 116206)

Antigen Details

Structure	Associated with glycoprotein A, 52 kD
Distribution	Early proerythroblast to mature erythrocyte, but not BFU-E and CFU-E
Cell Type	Erythrocytes
Biology Area	Immunology
Antigen References	1. Kina T, <i>et al.</i> 2000. <i>Br. J. Haematol.</i> 109:280.

- Ikuta K, *et al.* 1990. *Cell* 62:863.
- Osawa M, *et al.* 1996. *Weir's Handbook of Experimental Immunology*. Vol. 2 pp. 66.1-66.5.

Gene ID [104231](#)


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-mouse TER-119/Erythroid Cells, Biotin anti-mouse TER-119/Erythroid Cells, FITC anti-mouse TER-119/Erythroid Cells, PE anti-mouse TER-119/Erythroid Cells, PE/Cyanine5 anti-mouse TER-119/Erythroid Cells, Purified anti-mouse TER-119/Erythroid Cells, Alexa Fluor® 488 anti-mouse TER-119/Erythroid Cells, Alexa Fluor® 647 anti-mouse TER-119/Erythroid Cells, Alexa Fluor® 700 anti-mouse TER-119/Erythroid Cells, PE/Cyanine7 anti-mouse TER-119/Erythroid Cells, APC/Cyanine7 anti-mouse TER-119/Erythroid Cells, PerCP anti-mouse TER-119/Erythroid Cells, PerCP/Cyanine5.5 anti-mouse TER-119/Erythroid Cells, Brilliant Violet 421™ anti-mouse TER-119/Erythroid Cells, Pacific Blue™ anti-mouse TER-119/Erythroid Cells, Brilliant Violet 650™ anti-mouse TER-119/Erythroid Cells, Brilliant Violet 510™ anti-mouse TER-119/Erythroid Cells, Brilliant Violet 605™ anti-mouse TER-119/Erythroid Cells, Purified anti-mouse TER-119/Erythroid Cells (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse TER-119/Erythroid Cells, Brilliant Violet 785™ anti-mouse TER-119/Erythroid Cells, TotalSeq™-A0122 anti-mouse TER-119/Erythroid Cells, APC/Fire™ 750 anti-mouse TER-119/Erythroid Cells, TotalSeq™-B0122 anti-mouse TER-119/Erythroid Cells, TotalSeq™-C0122 anti-mouse TER-119/Erythroid Cells, Ultra-LEAF™ Purified anti-mouse TER-119/Erythroid Cells, Spark Blue™ 550 anti-mouse TER-119/Erythroid Cells, APC/Fire™ 810 anti-mouse TER-119/Erythroid Cells, Spark NIR™ 685 anti-mouse TER-119/Erythroid Cells Antibody

Product Data



C57BL/6 bone marrow cells stained with TER-119 FITC and anti-mouse CD45 APC

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587